Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT01984242
Brief Title: A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma (IMmotion150)

First Submitted : November 7, 2013
First Submitted that Met QC Criteria : November 7, 2013
First Posted : November 14, 2013 (Estimate)

Results First Submitted : October 11, 2017
Results First Submitted that Met QC Criteria : November 27, 2017
Results First Posted : December 21, 2017

Last Update Submitted that Met QC Criteria : May 20, 2019
Last Update Posted : May 22, 2019